Arrowhead Pharmaceuticals Aktie
8,85
EUR
-0,56
EUR
-5,99
%
9,99
USD
-0,27
USD
-2,59
%
Werbung
Arrowhead Pharmaceuticals Aktie Analyse
07.09.18 | Arrowhead Pharmaceuticals Buy | B. Riley FBR | |
06.09.18 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
08.08.18 | Arrowhead Pharmaceuticals Overweight | Cantor Fitzgerald | |
02.07.18 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
09.05.18 | Arrowhead Pharmaceuticals Overweight | Cantor Fitzgerald | |
12.02.18 | Arrowhead Pharmaceuticals Neutral | Cantor Fitzgerald | |
12.02.18 | Arrowhead Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
05.01.18 | Arrowhead Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
Werbung
|
|||
30.11.16 | Arrowhead Pharmaceuticals Mkt Perform | William Blair | |
30.11.16 | Arrowhead Pharmaceuticals Hold | Cantor Fitzgerald | |
30.11.16 | Arrowhead Pharmaceuticals Neutral | Chardan Capital Markets | |
10.11.16 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
19.05.16 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
09.10.14 | Arrowhead Pharmaceuticals Sector Perform | RBC Capital Markets |
Werbung
Werbung